The role of WNT10B expression in the prognosis of colorectal cancer: A retrospective study based on TCGA database and clinical data.

Lack of survival benefit of pelvic lymph node dissection for patients with radical prostatectomy and postprostatectomy radiotherapy.

Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma.

Oncological outcomes of concurrent nephroureterectomy during radical cystectomy: A propensity score-matched analysis with multivariable adjustment from Korean multicenter database.

Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.

Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.

Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study.

Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery.

Association of denosumab treatment with survival and skeletal-related events in Asian men with mCRPC: A real-world observational study.

Spread through air spaces (STAS) in lung adenocarcinoma: Prognostic impact of morphologic patterns, density, and extent.

Impact of pelvic lymph node dissection on oncological outcomes in patients with clinically staged non-muscle-invasive bladder cancer undergoing radical cystectomy: A systematic review.

Although a phase 3 trial did not demonstrate a survival benefit for gemcitabine, cisplatin, and nab-paclitaxel (Gem/Cis/Nab-P) in advanced biliary tract cancer (BTC), favorable outcomes were observed in specific patient subgroups, notably those with locally advanced disease or gallbladder carcinoma (GBC). This study aimed to assess the prognostic value of FDG PET/CT-derived parameters in advanced BTC patients treated with the Gem/Cis/Nab-P regimen, thereby identifying potential PET/CT imaging biomarkers that may aid in predicting survival benefit. We conducted a retrospective analysis of 125 advanced BTC patients who underwent pretreatment FDG PET/CT followed by Gem/Cis/Nab-P therapy. From the PET/CT images, maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of primary tumors were quantified. The influence of these parameters on prognostic outcomes was determined. Multivariate survival analysis identified TLG as an independent significant prognostic factor for both progression-free survival (PFS) and overall survival (OS) ( P <0.05). In subgroup analyses stratified by disease stage and TLG, patients with locally advanced disease and low TLG achieved the most favorable survival outcomes (median PFS, 18.4 months; median OS, not reached). Among tumor subtypes, TLG effectively differentiated PFS and OS in GBC patients, with the low TLG group exhibiting a median PFS of 11.7 months. TLG on pretreatment FDG PET/CT served as an independent prognostic biomarker for PFS and OS in advanced BTC. Locally advanced disease and low TLG, as well as GBC with low TLG, might be predictive of enhanced survival benefit from Gem/Cis/Nab-P therapy.

Impact of IDH mutation and MGMT methylation as Independent prognostic markers in uniformly treated high grade glioma Patients: A Real-World evidence in the Indian Population.

A multicenter, placebo-controlled clinical trial and preliminary experimental study exploring the efficacy of modified Banxia Xiexin Decoction in the treatment of advanced colorectal cancer.

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study.

Questioning adjuvant therapy and surveillance in octogenarians after right hemicolectomy.

Deep-learning/transfer-learning based Overall Survival prediction conditional on Progression-Free Interval with TCGA RNA-seq expression and KEGG-pathways.

Chronological age is an imperfect proxy for risk assessment in geriatric oncology. There is an urgent need for an objective, easily measurable biological aging signature to refine patient stratification and personalize therapeutic decisions. We analyzed a panel of seven aging-related biomarkers (including markers of inflammation, anabolic reserve, and telomere status) in 244 nonmetastatic breast cancer patients from two age groups ("Old", ≥70 years, N = 162; "Young", ≤60 years, N = 82). We used Latent Class Analysis (LCA) to integrate these markers and identify distinct biological risk profiles. These profiles were then evaluated for their association with Overall Survival (OS) and Cancer-Specific Death (CSD) via Competing Risk Analysis. LCA identified two patient profiles. The Unfavorable Biologic Profile (56.1% of the cohort) was defined by a triad of high MCP-1, high Chitinase activity, and low IGF-1. This profile was strongly associated with poorer OS (Age-adjusted HR=1.82, p = 0.018). Crucially, 15% of chronologically "Young" patients were assigned to this high-risk profile, while 23% of "Old" patients were assigned to the Favorable Profile. Furthermore, the Unfavorable Profile was more strongly and specifically associated with CSD (Subdistribution HR: 2.05, p = 0.012) than with Non-Cancer Death. Our results delineate an unfavorable, trans-chronological biological profile that identifies patients with low host reserve, largely driven by inflammaging and catabolism. This integrated signature provides a robust, objective screening tool to identify biologically frail patients, validating the need for Comprehensive Geriatric Assessment (CGA) and biomarker-guided therapeutic de-escalation (e.g., avoiding adjuvant chemotherapy) to improve individualized outcomes in oncology. BS32220096117.

We investigated changes in O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status in 21 patients with malignant gliomas who underwent two or more surgeries. Tumor specimens from multiple surgeries were analyzed using methylation-specific polymerase chain reaction (MS-PCR) and immunohistochemistry (IHC) for MGMT. Patients were divided into two groups: Group A (13 recurrent cases with therapeutic intervention) and Group B (8 cases of recurrence without therapeutic intervention or planned two-stage surgeries). MGMT methylation status was compared between initial and recurrent specimens, and in Group A, progression-free survival (PFS) and overall survival (OS) were analyzed according to MGMT methylation status at both initial and recurrent surgeries. By MS-PCR, changes in Group A were as follows: methylated to unmethylated in 23.1%, unchanged in 61.5%, and unmethylated to methylated in 15.4%. In Group B, changes were methylated to unmethylated in 12.5%, unchanged in 87.5%, and no cases of unmethylated to methylated. The difference in proportions between the groups was not significant (p = 0.13). By IHC, changes in Group A were methylated to unmethylated in 7.7%, unchanged in 53.8%, and unmethylated to methylated in 38.5%. In Group B, changes were methylated to unmethylated in 12.5%, unchanged in 87.5%, and no cases of unmethylated to methylated. The difference in proportions between the groups was significant (p = 0.034). Excluding one grade 3 case, in the 12 patients of Group A, median OS from treatment initiation differed by MGMT status assessed by immunohistochemistry in recurrent specimens (26.5 vs. 90.0 months, p = 0.043). These findings suggest that immunohistochemical assessment may capture spatial heterogeneity of MGMT status that is not readily detected by MS-PCR, and that therapeutic intervention may be associated with dynamic changes in MGMT methylation status. Furthermore, MGMT status assessed by IHC in recurrent specimens was associated with overall survival, indicating its potential prognostic relevance.

Long-term oncological outcomes after salvage surgery for anal squamous cell carcinoma - a national cohort study.